Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

NASDAQ:FATE

Overview | Financials
Company Name Fate Therapeutics, Inc.
Symbol FATE
Currency USD
Price 3.87
Market Cap 440,707,860
Dividend Yield 0%
52-week-range 1.63 - 8.83
Industry Biotechnology
Sector Healthcare
CEO Mr. J. Scott Wolchko
Website https://www.fatetherapeutics.com

An error occurred while fetching data.

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia;

Related Stocks

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

4.64 USD

Amicus Therapeutics, Inc. logo

Amicus Therapeutics, Inc.

FOLD

11.29 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

2.59 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

42.25 USD

Allscripts Healthcare Solutions, Inc. logo

Allscripts Healthcare Solutions, Inc.

MDRX

9.25 USD

Alignment Healthcare, Inc. logo

Alignment Healthcare, Inc.

ALHC

11.43 USD

Arvinas, Inc. logo

Arvinas, Inc.

ARVN

25.63 USD

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

1.72 USD

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

36.64 USD

Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

BEAM

25.65 USD

Financials

Numbers are in millions USD

Numbers are in millions USD